Puma Biotechnology, Inc. (PBYI) reported second-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter, the company had reported adjusted earnings of 10 cents. The above-adjusted loss excludes the impact of stock-based compensation expense. Including the same, the reported loss per share was 9 cents in the second quarter of 2024 against earnings of 5 cents reported in the year-ago quarter. In the second quarter, to ...

Puma Biotechnology Earnings Call Commercial Update August 1, 2024 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These sta ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Marc Frahm - TD Cowen Ed White - H.C. Wainwright Operator Good afternoon. My name is Diego and I will be your conference call operator today. [Operator Instructions] As a remi ...

Puma Biotech (PBYI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.16 per share when it actually produced a loss of $0.05, delivering a surprise of 68.75%. Over the last four quarters, the com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | |---------------------------------------------------------------------------------------|---------------------------------------- ...

News Release Exhibit 99.1 Puma Biotechnology Reports Second Quarter Financial Results LOS ANGELES, Calif., Aug. 1, 2024 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the second quarter 2024 compared to the second quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the sec ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Puma Biotechnology (PBYI) is a stock many investors are watching right now. PBYI is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Finally, investors will want to recognize that PBYI has a P/CF ratio of 6.55. This met ...

Shares of Puma Biotechnology, Inc. (PBYI) have plunged 38.4% in the past three months compared with the industry's decline of 4.8%. The company's sole marketed product, Nerlynx (neratinib), is approved for the treatment of early-stage HER2- positive breast cancer in patients who have been previously treated with Roche's (RHHBY) Herceptin-based adjuvant therapy. Demand for Nerlynx has been declining in recent quarters. Owing to this, sales of the drug have been falling over the past couple of quarters. Being ...

Company Participants Conference Call Participants Operator I would now like to turn the conference call over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. You may begin your conference. Thank you, Camilla. Good afternoon, and welcome to PumaÂ's conference call to discuss our Financial Results for the First Quarter of 2024. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of Puma Biotechnology; Maximo Nougues, Chief Financial O ...

Forward-Looking Safe-Harbor Statement Patients Sites of Care Academic Hospitals Community Hospitals Physician Practices Others (VA, DOD) Hub Services Specialty Pharmacy Network (SP) Specialty Distributor Network (SD) Acaria Health Accredo CVS ONCO360 Optum / Diplomat Biologics Cardinal Health McKesson ASD / Oncology Supply DMS Pharmaceutical Group Inc. Q1'2023 Q1'2024 +$2.1 mil -$2.0 mil Net Revenue (in $MM) Q1'2023 Q1'2024 +127 -120 2,881 2,410 Q4'2023 Q1'2024 Bottles ~67% of Patients in Q1'24 Started at a ...